In the present series of BOT (borderline ovarian tumour) with the largest number of patients treated conservatively to date, the presence of a MPP (micropapillary pattern) and the mucinous subtype were associated with a higher rate of progression to carcinoma after conservative management. These important results suggest that MBOT (mucinous BOT) belong to a ‘high-risk’... Continue Reading →

Although the term ‘borderline’ may suggest uncertainty, it accurately describes the ambiguous histologic and biologic features of these neoplasms and remains the most appropriate term. Accordingly, it has been recommended by the World Health Organization (WHO) for the last four decades [2]. The majority of these tumors are associated with a favorable prognosis and the... Continue Reading →

Annals of Oncology 25: 1320–1327, 2014 doi:10.1093/annonc/mdu119 Published online 11 March 2014 Borderline ovarian tumours (BOT) represent a distinct tumour entity of epithelial origin accounting for approximately 10%–20% of all ovarian neoplasms [1, 2]. In contrast to ovarian cancer, they are characterised by the absence of destructive stromal invasion. They are distinct by an epidemiological shift towards younger women and an excellent overall prognosis with a 5-year survival rate of more than 90% across all tumour stages [3–5]. Nevertheless, BOT may recur even after more than 10 years and undergo malignant transformation in selected cases [6].... Continue Reading →

ecancer 2013, 7:379 DOI: 10.3332/ecancer.2013.379 Epithelial tumours of the ovary can be either benign (cystadenomas) or malignant (cystadenocarcinomas). However, there is an intermediate state of epithelial tumours of the ovary called ‘borderline tumours’. Neither the oncological behaviour of this intermediate group of tumours nor the histological changes of the cells of the ovarian epithelium meet the specific... Continue Reading →